Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Mar 07, 2013

PTC THERAPEUTICS CLOSES $60 MILLION PRIVATE FINANCING

-Funds to support Phase 3 confirmatory trials of ataluren-

Dec 06, 2012

PTC THERAPEUTICS ANNOUNCES EUROPEAN MEDICINES AGENCY VALIDATION OF MARKETING AUTHORIZATION APPLICATION FOR ATALUREN IN DUCHENNE MUSCULAR DYSTROPHY

Enrollment for a Global Confirmatory Phase 3 Clinical Trial Planned for 1Q13

Nov 06, 2012

PTC THERAPEUTICS APPOINTS GEOFFREY McDONOUGH, M.D. TO BOARD OF DIRECTORS

SOUTH PLAINFIELD, NJ – November 6, 2012 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Geoffrey McDonough, M.D., to the company's Board of Directors. Dr. McDonough is the President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi), a leading European specialty

Oct 22, 2012

PTC Therapeutics Receives $1 Million Grant Award from the National Institutes of Health (NIH) to Support Research for a Treatment for Dengue Fever

SOUTH PLAINFIELD, NJ – October 22, 2012 – PTC Therapeutics, Inc. (PTC) today announced the receipt of a $1 million grant award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to discover antiviral agents for the treatment of dengue

Sep 28, 2012

PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors

PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors SOUTH PLAINFIELD, NJ – September 28, 2012 – PTC Therapeutics, Inc. (PTC) today announced the appointment of Jerome B. Zeldis, M.D., Ph.D., to the company's Board of Directors. Dr.

Jul 23, 2012

PTC THERAPEUTICS CLOSES $30 MILLION FINANCING

PTC THERAPEUTICS CLOSES $30 MILLION FINANCING SOUTH PLAINFIELD, NJ – July 23, 2012 – PTC Therapeutics, Inc. (PTC) today announced the completion of a $30 million financing. The round included a number of long-term investors such as Credit Suisse First Boston Equity Partners, HBM BioVentures,

Jul 11, 2012

PTC THERAPEUTICS ANNOUNCES ACHIEVEMENT OF MAJOR MILESTONE IN WELLCOME TRUST BMI1 COLLABORATION

- PTC Receives $2.3 Million Payment -

Jun 27, 2012

PTC THERAPEUTICS INITIATES OPEN-LABEL STUDY FOR ATALUREN IN PATIENTS WITH NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY

SOUTH PLAINFIELD, NJ – June 27, 2012 – PTC Therapeutics, Inc. (PTC) today announced the initiation of an open-label study in the European Union, Israel, Australia and Canada for patients with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who received ataluren in a prior,

Jun 08, 2012

Top-Line Data from Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results

- Data Demonstrate Positive Trends in Lung Function and Pulmonary Exacerbations -

Apr 02, 2012

PTC THERAPEUTICS ANNOUNCES EXECUTIVE PROMOTIONS

SOUTH PLAINFIELD, NJ – April 2, 2012 - PTC Therapeutics, Inc. (PTC) today announced the promotions of Cláudia Hirawat to President and Mark Boulding to Executive Vice President and Chief Legal Officer. "I am extremely pleased to announce these promotions.

Pagination

First page
Previous page
…
Page 53
Page 54
Current page 55
Page 56
Page 57
Next page
Last page